PepGen
Develops peptide-enabled oligonucleotide therapies with a clinical focus on myotonic dystrophy type 1.
$3.08
After-hours close−0.00 (−0.16%)
At close$3.09(+0.49%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 80.29%Insiders 27.71%
Institutions and insiders are filed separately and overlap, so together they can pass the whole company. No split is drawn from them.
Shares outstanding 69.17M · Float 36.05M · 52.1% free float
Institutions13F, as of Mar 31, 2026
102 holders · 55.53M shares · 29 new positions · 56 increased · 26 reduced · 21 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Ra Capital Management, L.P. | 20.06M | 29.01% | 0 | May 15, 2026 |
| Commodore Capital LP | 4.48M | 6.47% | +1.08M | May 15, 2026 |
| Viking Global Investors LP | 3.48M | 5.03% | 0 | May 15, 2026 |
| Laurion Capital Management LP | 2.75M | 3.98% | +698.7K | May 14, 2026 |
| Vivo Capital, LLC | 2.33M | 3.36% | 0 | May 20, 2026 |
| Millennium Management LLC | 2.08M | 3.01% | +1.88M | May 15, 2026 |
| Vanguard Capital Management LLC | 1.94M | 2.80% | +1.94Mnew | May 15, 2026 |
| Awm Investment Company, Inc. | 1.83M | 2.65% | +530.9K | May 15, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| RA Capital Management, L.P.incl. RA Capital Healthcare Fund, L.P., Peter Kolchinsky +1 more | 29.20% | 20.10M | 13D | Sep 30, 2025 ↗ |
| Oxford Science Enterprises plc | 7.20% | 4.96M | 13G | Oct 1, 2025 ↗ |
| Ein # | 7.20% | 2.34M | Nov 14, 2024 ↗ | |
| Commodore Capital LP | 6.50% | 4.48M | 13G | May 15, 2026 ↗ |
| Viking Global Investors LP | 5.03% | 3.48M | 13G | May 15, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Ra Capital Management, L.P. | director, 10 percent owner: | 18.55M | 26.82% | Sep 30, 2025 |
| Oxford Science Enterprises plc | other: Former 10% Owner | 4.96M | 7.16% | Oct 1, 2025 |
| James G. McArthur | director, officer: President and CEO | 296.3K | 0.43% | Mar 6, 2026 |
| Noel Donnelly | officer: Chief Financial Officer | 111.6K | 0.16% | Mar 6, 2026 |
| Paul Streck | officer: EVP, Head of R&D | 76.2K | 0.11% | Mar 6, 2026 |
| Joseph Vittiglio | officer: Chief Business & Legal Officer | 65.7K | 0.10% | Mar 2, 2026 |
| Kasra Kasraian | officer: Chief Technical Officer | 50.1K | 0.07% | May 26, 2026 |
| Mary Beth DeLena | officer: General Counsel | 15.0K | 0.02% | Mar 5, 2025 |
2 ten-percent owners hold 5.22M shares by Form 4 — the 13D/G table above shows those stakes, the figure above counts officers and directors only · 3 people have not refiled in the last 18 months (1.78M shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| May 21, 2026 | Kasra Kasraianofficer: Chief Technical Officer | Sale | 1,233 | $1.41 | 50,074 |
| Mar 4, 2026 | James G. McArthurdirector, officer: President and CEO | Sale · 2 lots | 5,275 | $6.23 | 296,326 |
| Mar 4, 2026 | Noel Donnellyofficer: Chief Financial Officer | Sale · 2 lots | 2,084 | $6.23 | 111,603 |
| Mar 4, 2026 | Paul Streckofficer: EVP, Head of R&D | Sale · 2 lots | 1,879 | $6.23 | 76,226 |
| Sep 30, 2025 | Oxford Science Enterprises plcother: Former 10% Owner | Purchase | 200,000 | $3.20 | 4,955,388 |
| Sep 26, 2025 | Ra Capital Management, L.P.director, 10 percent owner: | Purchase | 9,375,000 | $3.20 | 18,554,273 |
CongressHouse and Senate disclosures
Not reported.